HBIO vs MLAB vs RGEN vs WAT

For growth investors, Repligen Corporation (RGEN) is the stronger pick with 16.

4% revenue growth year-over-year, versus -8. 1% for Harvard Bioscience, Inc. (HBIO). Waters Corporation (WAT) offers the better valuation at 32. 6x trailing P/E (24. 4x forward), making it the more compelling value choice. Analysts rate Harvard Bioscience, Inc. (HBIO) a "Buy" — based on 5 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

On trailing P/E, Waters Corporation (WAT) is the cheapest at 32.

6x versus Repligen Corporation at 147. 0x. On forward P/E, Mesa Laboratories, Inc. is actually cheaper at 11. 7x — notably different from the trailing picture, reflecting expected earnings growth.

Over the past 5 years, Waters Corporation (WAT) delivered a total return of +11.

3%, compared to -90. 7% for Harvard Bioscience, Inc. (HBIO). Over 10 years, the gap is even starker: RGEN returned +369. 1% versus HBIO's -76. 2%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Waters Corporation (WAT) is the lower-risk stock at 1.

07β versus Harvard Bioscience, Inc. 's 2. 03β — meaning HBIO is approximately 90% more volatile than WAT relative to the S&P 500. On balance sheet safety, Repligen Corporation (RGEN) carries a lower debt/equity ratio of 33% versus 3% for Harvard Bioscience, Inc. — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), Repligen Corporation (RGEN) is pulling ahead at 16.

4% versus -8. 1% for Harvard Bioscience, Inc. (HBIO). On earnings-per-share growth, the picture is similar: Repligen Corporation grew EPS 287. 0% year-over-year, compared to -357. 1% for Harvard Bioscience, Inc.. Over a 3-year CAGR, MLAB leads at 9. 3% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Waters Corporation (WAT) is the more profitable company, earning 20.

3% net margin versus -65. 5% for Harvard Bioscience, Inc. — meaning it keeps 20. 3% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: WAT leads at 28. 2% versus -0. 7% for HBIO. At the gross margin level — before operating expenses — MLAB leads at 62. 6%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

On forward earnings alone, Mesa Laboratories, Inc.

(MLAB) trades at 11. 7x forward P/E versus 64. 3x for Repligen Corporation — 52. 5x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for RGEN: 32. 9% to $168. 00.

In this comparison, MLAB (0.

6% yield) pays a dividend. HBIO, RGEN, WAT do not pay a meaningful dividend and should not be held primarily for income.

For long-horizon retirement investors, Waters Corporation (WAT) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 1.

07), +162. 0% 10Y return). Harvard Bioscience, Inc. (HBIO) carries a higher beta of 2. 03 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (WAT: +162. 0%, HBIO: -76. 2%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

These companies operate in different sectors (HBIO (Healthcare) and MLAB (Technology) and RGEN (Healthcare) and WAT (Healthcare)), which means they face different economic cycles, regulatory environments, and macro sensitivities — making direct comparison nuanced.

In terms of investment character: HBIO is a small-cap quality compounder stock; MLAB is a small-cap quality compounder stock; RGEN is a small-cap high-growth stock; WAT is a mid-cap quality compounder stock. MLAB pays a dividend while HBIO, RGEN, WAT do not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.